[O7] Oral Session 7　Gastrointestinal Cancer 2（Lower GI Tract-Colorectal Cancer 1）
【E】

[O7-3] Pembrolizumab vs chemotherapy in MSI-H / dMMR metastatic colorectal cancer: KEYNOTE-177 final analysis Asia subgroup

^○Takayuki Yoshino¹, Thierry Andrɲ, Kai-Keen Shiu³, Tae Won Kim⁴, Benny Vittrup Jensen⁵, Lars Henrik Jensen⁶, Cornelius J. A. Punt⁷, Denis Smith⁸, Rocio Garcia-Carbonero⁹, Peter Gibbs¹⁰, T. Le Dung¹¹, Noriaki Adachi¹², David Fogelman¹³, Patricia Marinello¹³, Luis A. Diaz Jr.¹⁴ (1.National Cancer Center Hospital East, 2.Hopital Saint-Antoine, Paris, France, 3.University College Hospital, NHS Foundation Trust, London, UK, 4.Asan Medical Center, Seoul, South Korea, 5.Herlev and Gentofte Hospital, Herlev, Denmark, 6.University Hospital of Southern Denmark, Vejle, Denmark, 7.Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands, 8.Hopital Haut Leveque, Pessac, France, 9.Hospital Universitario 12 de Octubre, Imas12, UCM, Madrid, Spain, 10.Western Hospital, Footscray, VIC, Australia, 11.Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA, 12.MSD KK, Tokyo, Japan, 13.Merck & Co., Inc., Kenilworth, NJ, USA, 14.Memorial Sloan Kettering Cancer Center, New York, NY, USA)